To Evaluate efficacy and tolerability of IFN Beta-1a SC Treatment and Predictive Value of 6-Month MRI

Trial Profile

To Evaluate efficacy and tolerability of IFN Beta-1a SC Treatment and Predictive Value of 6-Month MRI

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms PRISMS; PRISMS-2
  • Most Recent Events

    • 28 Oct 2017 Results assessing the association of MAGNIMS score at Year 1 with long-term clinical disease activity status and disability progression, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 27 Jun 2017 Results (n=917) assessing predictive value of modified Rio score using patient data from REFLEX(ION), REGARD, SPECTRIMS and PRISMS trials presented at the 3rd Congress of the European Academy of Neurology
    • 25 May 2017 According to an EMD Serono media release, data from this trial were accepted for presentation at the 31st Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top